Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis
Authors:
- 1 January 2025
- journal article
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (8) , 3417-3433
Abstract
ZUMA-24 is a Phase 2, open-label, multicenter study that investigated safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, administered in the outpatient setting to patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) with ≥1 prior lines of therapy. Patients underwent leukapheresis and received lymphodepleting chemotherapy, axi-cel infusion (2×106 CAR T cells/kg), and prophylactic steroids. Patients were monitored daily ≥7 days after infusion per institutional outpatient monitoring guidelines. The primary endpoint was incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs). Median follow-up was 13 months for 30 patients treated with outpatient axi-cel. Grade 1-2 CRS was reported in 90% of patients, with no grade ≥3 CRS. NEs of any grade were reported in 80% of patients (grade ≥3, 23%; no patients died due to NEs). Median time to onset was 4 days for CRS and 7 days for NEs, with a median duration of 5 days and 6 days, respectively. All patients experienced AEs of any grade (grade ≥3, 83%). After axi-cel, 93% of patients were hospitalized, with 4 days median time to first hospitalization (8 days median stay), and 4 patients (13%) were admitted to the ICU (for 2-7 days). Among patients evaluable for efficacy (n=29), the objective response rate was 93% (complete response, 76%), with a median duration of response of 11.4 months. These results support safety and feasibility of outpatient administration of axi-cel. This trial is registered at ClinicalTrials.gov: #NCT05459571.Keywords
This publication has 28 references indexed in Scilit:
- Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient AdministrationTransplantation and Cellular Therapy, 2021
- Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementBlood Advances, 2020
- Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell TherapyJournal of the Advanced Practitioner in Oncology, 2019
- Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United StatesJournal of Medical Economics, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014